Children With and Without Allergic Asthma Experience Less Exacerbation When Dupilumab Is Used.

Published Date: 27 Apr 2023

Children With and Without Allergic Asthma Experience Less Exacerbation After Receiving Dupilumab.

Read Full News

Latest News

Insurance Formularies Holding Up Lower-Emission Asthma, COPD Inhalers

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

7 Pulmonology Headlines You Missed in August 2026 Victoria Johnson

August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.

Lung Cancer Diagnosis Linked to Lung Microplastic Presence, Quantity Victoria Johnson

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Why Doctors Need to Complete the COPD or Asthma Workup to Rule Out Alpha-1 Kyle Hogarth, MD

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Childhood Pollution Exposure May Trigger COPD Polygenic Risk Victoria Johnson

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

Todays Updates

Evaluating Zeleciment Basivarsen in Myotonic Dystrophy Type 1: The Phase 3 HARMONIA Trial Isabella Ciccone, MPH

The phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.

Zilucoplan Autoinjector Matches Bioequivalence of Pre-Filled Syringe in Myasthenia Gravis Marco Meglio

New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.

Global Phase 3 UPSTREAM MG Trial of Telitacicept Advances Enrollment in Generalized Myasthenia Gravis Isabella Ciccone, MPH

The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.

EpilepsyGTx, Viralgen Partner on AAV Gene Therapy EPY201 Ahead of Planned First-in-Human Trial Louie Pasculli

EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.

New Phase 3 Trials to Test Empasiprubart Against Placebo, IVIG in CIDP Louie Pasculli

Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy.

NeuroVoices: James Winkley, MD, on Analyzing Phase 3 PREVAIL Trial of Gefurulimab Marco Meglio

The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Todays Updates

Evaluating Zeleciment Basivarsen in Myotonic Dystrophy Type 1: The Phase 3 HARMONIA Trial Isabella Ciccone, MPH

The phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.

Zilucoplan Autoinjector Matches Bioequivalence of Pre-Filled Syringe in Myasthenia Gravis Marco Meglio

New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.

Global Phase 3 UPSTREAM MG Trial of Telitacicept Advances Enrollment in Generalized Myasthenia Gravis Isabella Ciccone, MPH

The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.

EpilepsyGTx, Viralgen Partner on AAV Gene Therapy EPY201 Ahead of Planned First-in-Human Trial Louie Pasculli

EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.

New Phase 3 Trials to Test Empasiprubart Against Placebo, IVIG in CIDP Louie Pasculli

Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy.

NeuroVoices: James Winkley, MD, on Analyzing Phase 3 PREVAIL Trial of Gefurulimab Marco Meglio

The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Latest News

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

News All Time

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

Oral STAT6 Degraders Fill Niche in Asthma Care, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD Wim Wuyts, MD, PhD

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD Surya P. Bhatt, MD

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

STAT6 Degradation: A Novel Oral Target for Asthma? Victoria Johnson

At ERS 2026, pulmonologists framed oral STAT6 degradation—led by Kymera's KT-621—as a potential biologic-like, access-expanding approach.

ERS Congress 2026: 6 Late-Breaking Trials to Know Victoria Johnson

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Bridging the ROS1 Divide: Translating Biomarker Insights and Therapeutic Advances Into Community Oncology Practice for NSCLC

Bridging the ROS1 Divide: Translating Biomarker Insights and Therapeutic Advances Into Community Oncology Practice for NSCLC

Innovations in NSCLC: Outlooks on Clinical Trials and Emerging Bispecific ADCs

Innovations in NSCLC: Outlooks on Clinical Trials and Emerging Bispecific ADCs

FDA Says Juul Can Sell Updated Vaping Device With Age-Gating Technology

Agency allows company to sell a new version of its top-selling device

My Job Has Become Mounds of Paperwork. Work Requirements Will Make it Worse.

The new Medicaid rule is unworkable

Recommended News For You

Whole Foods Recall; RFK Jr.'s Voting Problem; Glass Particles in Biosimilar

No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire

Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam Method

Inadvertent lung cancer screening results are discussed in a new study.

Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.

Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?

Patients value communication skills from cancer surgeons across six key areas, according to research

Recommended Articles For You

Clonal Hematopoiesis Dynamics and Future Hematologic Outcomes 

Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes 

What is Hemorrhagic Cystitis and How to Manage its Symptoms 

Molecular Glue Therapy for Resistant Cancers 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

9/11's Latest Wave of Cancers, 25 Years On

2.

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

3.

Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care

4.

Chemoradiation Plus Immunotherapy Fails to Improve Survival in Limited-Stage SCLC

5.

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

1.

Connected Cancer Survivorship Platforms: Transforming Post-Treatment Care Through Digital Integration

2.

World Congress on Oncology & Cancer Care 2026: Advances, Challenges, and Future Directions

3.

Mast Cell-Tumor Cell Interactions in OSCC: Genetic and microRNA Insights

4.

How Cancer Cells Evade Immune Destruction and the Fight Back

5.

Machine Learning in Hematology: Boosting Diagnostic Precision and Speed in Medical Practice

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Blood Clotting Disorders Explained

2.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

3.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment

4.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

5.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot